Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 5/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.41 |
| ▸ | SDHA | P31040 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CALML3 | P27482 | 1/20 | 0.41 |
| ▸ | CMA1 | P23946 | 2/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6239683 | 1.00 | ENPP2 (0.47) | ENPP2MAOAMAOBPTGS1SDHA | |
| SCHEMBL6238457 | 0.95 | ENPP2 (0.47) | ENPP2MAOAMAOBPTGS1SDHA | |
| SCHEMBL6238466 | 0.95 | ENPP2 (0.47) | ENPP2MAOAMAOBPTGS1SDHA | |
| SCHEMBL6237003 | 0.92 | MAOA (0.44) | ENPP2MAOAMAOBPTGS1SDHA | |
| SCHEMBL6236996 | 0.92 | MAOA (0.44) | ENPP2MAOAMAOBPTGS1SDHA | |
| SCHEMBL6241236 | 0.92 | MAOA (0.42) | ENPP2MAOAMAOBPTGS1SDHA | |
| SCHEMBL6241227 | 0.92 | MAOA (0.42) | ENPP2MAOAMAOBPTGS1SDHA | |
| SCHEMBL6236918 | 0.90 | MAOA (0.44) | ENPP2MAOAMAOBPTGS1SDHA | |
| SCHEMBL6236917 | 0.90 | MAOA (0.44) | ENPP2MAOAMAOBPTGS1SDHA | |
| SCHEMBL6240792 | 0.89 | MAOA (0.47) | MAOAMAOBPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288273-A1 | Antibacterial agents | BOYER FREDERICK E JR | 2005-12-29 | — | — | US | claimed |
| EP-1594865-A2 | ANTIBACTERIAL AGENTS | Warner-Lambert Company LLC (US) | 2005-11-16 | — | — | EP | claimed |
| WO-2004069832-A2 | ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2004-08-19 | — | — | WO | claimed |
| US-20050288273-A1 | Antibacterial agents | BOYER FREDERICK E JR | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288273-A1 | Antibacterial agents | MRPL21, RPN2, FBL | ENPP2 1914/4885MAOA 236/4885MAOB 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.